Bruce E. Sands

educated at: University of Pennsylvania, Boston University School of Medicine

award received: Fellow of the American Gastroenterological Association

Bruce E. Sands is an American gastroenterologist, focusing in colonoscopy, Crohn's disease, inflammatory bowl disease, ulcerative colitis and upper GI endoscopy, currently the Dr. Burrill B. Crohn Professor of Medicine at Mount Sinai School of Medicine and is an Elected Fellow of the American College of Gastroenterology and American Gastroenterological Association. Source: Wikipedia (en)

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 191

Date

Title

Authors

2020-02-13

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

Monika Fischer, Bruce E. Sands, William Jeffery Sandborn, Edward V Loftus
2020-01-01

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply

Bruce E. Sands
2020-01-01

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply

Bruce E. Sands
2020-01-01

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease

Subrata Ghosh, Bruce E. Sands, William Jeffery Sandborn, Paul Rutgeerts, Omoniyi J Adedokun, Brian G. Feagan, Stephen B Hanauer, Christopher Gasink, Douglas Jacobstein
2020-05-01

Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply

William Jeffery Sandborn, Silvio Danese, Jean-Frederic Colombel, Bruce E. Sands
2020-06-01

Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply

William Jeffery Sandborn, Walter Reinisch, Silvio Danese, Bruce E. Sands, Nervin Lawendy, Nana Koram, Haiyun Fan, Irene Modesto
2020-06-01

The day after COVID-19 in IBD: how to go back to 'normal'

Silvio Danese, Bruce E. Sands, Siew Chien Ng, Laurent Peyrin-Biroulet
2020-06-25

Ileocolic anastomotic inflammation after resection for Crohn's disease indicates disease recurrence: a histopathologic study

Bruce E. Sands
2020-06-11

Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1

Edward V Loftus, Bruce E. Sands, Javaria Mona Khalid
2020-07-13

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease

Matthew Bohm, Siddharth Singh, Robert P Hirten, Ryan Ungaro, Arun Swaminath, Jean-Frederic Colombel, Edward V Loftus, William Jeffery Sandborn, Parambir Dulai, Monika Fischer, Bruce E. Sands
2020-07-22

Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments

Klaus Gottlieb, Harris A Ahmad, Ryan Stidham, Walter Reinisch, Bruce E. Sands
2020-07-23

Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study

Bruce E. Sands, Laurie Keefer
2020-08-21

The role of resilience in irritable bowel syndrome, other chronic gastrointestinal conditions and the general population

Bruce E. Sands
2020-08-24

Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis

Laurent Peyrin-Biroulet, Bruce E. Sands, David T Rubin, William Jeffery Sandborn, Brian G. Feagan, Colleen W Marano, Joshua R Friedman
2020-09-01

Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management

Bruce E. Sands
2020-09-02

Long-term safety of vedolizumab for inflammatory bowel disease

Edward V Loftus, Brian G. Feagan, Remo Panaccione, Jean-Frederic Colombel, William Jeffery Sandborn, Bruce E. Sands, Silvio Danese, Geert D'Haens, David T Rubin, Richard A Lirio, Séverine Vermeire, Ira Shafran
2020-09-23

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

Bruce E. Sands, William Jeffery Sandborn, Silvio Danese
2020-09-24

Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease

Eric E Schadt, Bruce E. Sands, Judy H. Cho
2020-10-08

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis

Monika Fischer, Bruce E. Sands, William Jeffery Sandborn, Edward V Loftus
2020-10-21

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy

Remo Panaccione, Silvio Danese, William Jeffery Sandborn, Omoniyi J Adedokun, Tadakazu Hisamatsu, Ramesh P Arasaradnam, Stephan R. Targan, Bruce E. Sands
2020-10-27

Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis

Laurent Peyrin-Biroulet, Bruce E. Sands, William Jeffery Sandborn
2020-11-01

Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease

Ryan Ungaro, Jeffrey S Hyams, Bruce E. Sands, Subra Kugathasan, Judy H. Cho
2020-11-20

Pregnancy and Neonatal Outcomes after Fetal Exposure To Biologics and Thiopurines among Women with Inflammatory Bowel Disease

Bruce E. Sands, William Jeffery Sandborn
2020-12-21

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Iris Dotan, Walter Reinisch, Laurent Peyrin-Biroulet, Bruce E. Sands, Anne M. Griffiths, David T Rubin, William Jeffery Sandborn, Jean-Frederic Colombel, Maria T Abreu, Axel Dignass, Silvio Danese
2020-12-31

Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare

Bruce E. Sands, Laurie Keefer
2020-12-31

Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease

Bruce E. Sands, Judy H. Cho, Richard Flavell
2019-03-01

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1

Brian G. Feagan, Silvio Danese, Bruce E. Sands, Walter Reinisch, James D Lewis
2019-01-01

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies

Bruce E. Sands, David T Rubin
2019-01-22

Gut microbiota density influences host physiology and is shaped by host and microbial factors

Eduardo Contijoch, Graham J Britton, Jose C Clemente, Antonio F Di Narzo, Joshua R Friedman, Judy H. Cho, Jeremiah J Faith, Eric E Schadt, Iris Dotan, Bruce E. Sands
2019-01-01

Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice.

Graham J Britton, Eduardo Contijoch, Jonathan Braun, Jean-Frédéric Colombel, Dermot McGovern, Miriam Merad, Bruce E. Sands, Jose C Clemente
2019-06-01

A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory Bowel Disease

Bruce E. Sands
2019-09-01

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

Bruce E. Sands, Maria T Abreu, Stephan R. Targan, Laurent Peyrin-Biroulet, Silvio Danese, Remo Panaccione, William Jeffery Sandborn, Colleen W Marano, Omoniyi J Adedokun

Human - wd:Q29922058

Welcome to Inventaire

the library of your friends and communities

learn more